Oxford, United Kingdom
PrecisionLife is a clinical-stage precision medicine company focusing on better diagnostic tools and more personalized treatment options for predicting, treating, and preventing complex chronic diseases. Their AI-led platform is unmatched in understanding disease biology and identifying underlying causes of disease and biomarkers to stratify patients by molecular mechanism. These insights and mechanistic® tests accurately link individuals to drug targets, clinical trials, and treatments, thereby increasing the probability of success in drug development. PrecisionLife aims to reduce the global burden of chronic disease and improve health for billions of people.
Founded in 2015, PrecisionLife operates in the biotechnology and health care industries, with headquarters in the United Kingdom. The company recently secured a €2.50M grant investment on 20 February 2025, with the European Innovation Council backing this latest development. With its focus on leveraging AI for precision medicine, PrecisionLife is positioned to make a significant impact on the diagnosis, treatment, and prevention of chronic diseases.
